Treatment of gastrointestinal viruses

M J Farthing1

  • 1Digestive Diseases Research Centre, St Bartholomew's & Royal London School of Medicine & Dentistry, Turner Street, London E1 2AD, UK.

Novartis Foundation Symposium
|July 11, 2001
PubMed

Insights

Oral rehydration therapy (ORT) is crucial for managing childhood diarrhea. Reducing the salt concentration in oral rehydration solutions (ORS) enhances treatment effectiveness and safety for viral and bacterial diarrheal diseases.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Pediatrics

Background:

  • Common enteric viruses like rotavirus cause mild to moderate diarrhea.
  • Standard management focuses on fluid and electrolyte balance.
  • Oral rehydration therapy (ORT) has significantly reduced childhood mortality.

Purpose of the Study:

  • To review the efficacy of oral rehydration solutions (ORS) in managing acute diarrhea.
  • To explore advancements in ORS formulation and other therapeutic interventions.
  • To discuss Cytomegalovirus (CMV) gastrointestinal infections and their treatment.

Main Methods:

  • Review of existing literature on ORS and antiviral therapies.
  • Analysis of the impact of reduced osmolality in ORS.
  • Examination of treatment protocols for Cytomegalovirus (CMV) infections.

Main Results:

  • Hypotonic oral rehydration solutions (ORS) are safe and effective for acute childhood diarrhea.
  • Complex substrate ORS shows increased efficacy in cholera.
  • Ganciclovir or foscarnet are effective for Cytomegalovirus (CMV) gastrointestinal infections, with combined therapy for resistant cases.

Conclusions:

  • Hypotonic ORS represents a significant improvement over standard ORT.
  • While some novel treatments are experimental, standard rehydration remains key.
  • Cytomegalovirus (CMV) gastrointestinal infections require specific antiviral treatment, often dual therapy.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...